Quad-C Management, Inc. (“Quad-C”), a leading middle market private equity firm, announces its investment in Dane Street, a national leader in the insurance and healthcare services industry and provider of Independent Medical Examination and Peer Review services to over 300 clients. Founded in 2008 by Will Fulton and based in Palm Beach Gardens, FL, Dane
Quad-C Management Announces Investment in Dane Street Read More »
You are unauthorized to view this page. Username Password Remember Me Forgot Password
LongueVue Capital (“LVC”), a New Orleans-based private equity firm, announced a strategic investment in Apex Dental Laboratory Group (“Apex” or the “Company”), a leading dental laboratory platform serving dental practices across the United States. Swaney Group Capital (“SGC”), a Tampa-based private equity firm, partnered with LVC to consummate the transaction. Founded in 2015 and headquartered
You are unauthorized to view this page.
KKR and Taiyo Holdings Agree to Privatization to Accelerate Long-Term Growth Read More »
Eli Lilly and Company (NYSE: LLY) and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, announces a definitive agreement for Lilly to acquire Centessa. Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists designed to address
Lilly to Acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders Read More »
KKR, a leading global investment firm, and Taiyo Holdings Co., Ltd. (“Taiyo Holdings” or the “Company”; TSE stock code 4626), announce that KJ005 Co., Ltd. (the “Offeror”), an entity owned by investment funds managed by KKR, intends to make a tender offer to acquire all the common shares of Taiyo Holdings (the “Tender Offer”). Taiyo
KKR and Taiyo Holdings Agree to Privatization to Accelerate Long-Term Growth Read More »
Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announce the companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share
Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announces the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States. The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical
